Preferred Label : adrenoleukodystrophy;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations-ald-region
2025
France
scientific and technical information
due to
fructose-bisphosphate aldolase
adrenoleukodystrophy
chronic disease

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/prevalence-beneficiaires-ald-region
2025
France
scientific and technical information
reference standards
fructose-bisphosphate aldolase
Workforce
chronic disease
due to
prevalence
adrenoleukodystrophy

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/prevalence-beneficiaires-ald-departement
2025
France
scientific and technical information
fructose-bisphosphate aldolase
adrenoleukodystrophy
prevalence
reference standards
due to
Workforce
chronic disease

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/prevalence-beneficiaires-ald
2025
France
scientific and technical information
chronic disease
prevalence
Workforce
adrenoleukodystrophy
fructose-bisphosphate aldolase
due to

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations
2025
France
scientific and technical information
due to
incidence
chronic disease
fructose-bisphosphate aldolase
adrenoleukodystrophy

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations-ald-departement
2025
France
scientific and technical information
chronic disease
fructose-bisphosphate aldolase
due to
adrenoleukodystrophy

---
https://igas.gouv.fr/protection-sociale/revue-de-depenses-relative-aux-affections-de-longue-duree-ald-pour-un-dispositif-plus-efficient-et-equitable
2025
France
technical report
adrenoleukodystrophy
affect, nos
efficiency
equipment and supplies
duration
affect
Set, Psychology
device, nos
chronic disease
expenditures
disease, nos
health expenditures
devices

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations-ald-tumeur-maligne
2025
France
scientific and technical information
due to
adrenoleukodystrophy
incidence
neoplasms
fructose-bisphosphate aldolase
chronic disease
neoplasms by site

---
https://www.assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations-ald-vih-departement
2025
France
scientific and technical information
due to
adrenoleukodystrophy
fructose-bisphosphate aldolase
hiv infections
human immunodeficiency virus infection, nos
chronic disease

---
https://assurance-maladie.ameli.fr/etudes-et-donnees/incidence-nouvelles-exonerations
2023
France
scientific and technical information
ABCD1 wt Allele
Number
incidence
fructose-bisphosphate aldolase
chronic disease
adrenoleukodystrophy
Characteristic

---
https://www.ors-na.org/publications/estimation-des-besoins-potentiels-en-education-therapeutique-du-patient-approche-via-la-prevalence-des-ald/
2023
France
technical report
needs
appraiser
Respect
prevalence
education
therapeutics
Treatments
patient education as topic
fructose-bisphosphate aldolase
Therapeutics
chronic disease
patient need for
health services needs and demand
adrenoleukodystrophy

---
https://www.has-sante.fr/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=c_534288
2021
France
practice guideline
fructose-bisphosphate aldolase
affect, nos
affect
adrenoleukodystrophy
N syndrome
disease, nos
chronic disease
Handbook
N syndrome
duration

---
https://www.has-sante.fr/portail/jcms/c_618458/fr/ald-n-14-actes-et-prestations-sur-l-asthme-actualisation-octobre-2017
2017
false
false
false
France
French
scientific and technical information
asthma, nos
secondary
respiratory insufficiency
chronic respiratory failure
chronic disease
Health Care Category
asthma
asthma
adrenoleukodystrophy
severe
fructose-bisphosphate aldolase

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.